ArticleAntimicrobial agents and chemotherapy2004
Efficacy of posaconazole in a murine model of central nervous system aspergillosis.
Article in Antimicrobial agents and chemotherapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 60 citations in OpenAlex.
- Antibacterial Potential of Lucilia sericata (Meigen, 1826) (Diptera: Calliphoridae) Maggot Excretions/Secretions in Presence of Human Tear Fluid.Neotropical entomology · 2025Article
- Successful Treatment of RefractoryClinical case reports · 2025Article
- Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model.PLoS neglected tropical diseases · 2016Article
- Reflections on the approach to treatment of a mycologic disaster.Antimicrobial agents and chemotherapy · 2013Article
- Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity.Antimicrobial agents and chemotherapy · 2012Article
- Current concepts in antifungal pharmacology.Mayo Clinic proceedings · 2011Review
- Posaconazole: A new agent for the prevention and management of severe, refractory or invasive fungal infections.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2008Article
- Rapid detection of triazole antifungal resistance in Aspergillus fumigatus.Journal of clinical microbiology · 2008Article
- Assessment of the paradoxical effect of caspofungin in therapy of candidiasis.Antimicrobial agents and chemotherapy · 2006Article
- Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.Antimicrobial agents and chemotherapy · 2005Article
- Efficacy of caspofungin against central nervous system Aspergillus fumigatus infection in mice determined by TaqMan PCR and CFU methods.Antimicrobial agents and chemotherapy · 2005Article
- Posaconazole.Drugs · 2005Review
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human central nervous system (CNS) aspergillosis has >90% mortality. We compared posaconazole with other antifungals for efficacy against murine CNS aspergillosis. All tested regimens of posaconazole were equivalent to those of amphotericin B and superior in prolonging survival and reducing CFU to those of itraconazole and caspofungin and to vehicle controls. No antifungal regimen effected cure. No toxicity was noted. Overall, posaconazole shows potential for treating CNS aspergillosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.